Compare Twist Bioscience Corp (TWST) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Xpeng Inc - ADR — how do they compare? Twist Bioscience Corp trades at $159.78 (market cap $10.08B), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: Twist Bioscience Corp and Xpeng Inc - ADR are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Xpeng Inc - ADR for 80 Days on average.
| TWST | XPEV | |
|---|---|---|
Market Cap | $10.08B | $9.16B |
Volume | 4,229,037 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $205.00 | $28.07 |
52-Week Low | $25.45 | $9.25 |
Typical Hold Time | 27 Days | 80 Days |
Enterprise Value | $10.01B | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
XPeng (XPEV) trades at $9.55, down 0.31% with bearish technical signals despite analyst optimism. The company shows strong revenue growth to $76.72B in 2025 but remains unprofitable with a -$1.14B net loss. Recent vehicle deliveries of 41,256 units in September 2026 and upcoming G9L SUV launch at Paris Motor Show highlight expansion efforts. Cash flow improved significantly with $8.26B from operations in 2025, though negative earnings surprises in Q1 and Q2 2026 raise execution concerns.
XPeng presents a high-risk growth opportunity with 58.8% analyst buy ratings and $17.55 price target suggesting 84% upside. However, persistent losses, competitive EV market pressures, and technical bearishness create significant headwinds. The stock's appeal hinges on successful Physical AI and robotics commercialization alongside sustained delivery growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
